Uckun F M, Gesner T G, Song C W, Myers D E, Mufson A
Department of Therapeutic Radiology-Radiation, University of Minnesota Health Sciences Center, Minneapolis 55455.
Blood. 1989 Feb;73(2):533-42.
The purpose of this study was to analyze the expression of functional interleukin-3 (IL-3) receptors on leukemic B-cell precursors (BCPs) from 12 BCP acute lymphoblastic leukemia (ALL) patients and five BCP ALL cell lines. The specific binding of biosynthetically labeled 35S-recombinant (r) IL-3 to freshly obtained leukemic marrow blasts was initially investigated. In five of 12 BCP ALL cases, the binding of 35S-rIL-3 was markedly blocked by excess cold rIL-3, and the percentage of inhibitable binding ranged from 53% to 78% (mean +/- SE = 65% +/- 4%). In these cases, the cell-bound radioactivity ranged from 146 cpm/10(7) cells to 1,433 cpm/10(7) cells (mean +/- SE = 627 +/- 250 cpm/10(7) cells), indicating that 1 to 14 femtomole (mean +/- SE = 6 +/- 2 fms) of [35S]rIL-3/10(7) cells were specifically bound (= 60 to 840 molecules per cell). rIL-3 stimulated the proliferative activity of leukemic BCPs in a dose-dependent fashion without inducing differentiation, and the half-maximal stimulatory activity was observed at a concentration of 17 to 34 pmol/L. Fluorescence-activated cell sorter (FACS)-isolated virtually pure populations of CD10+CD19+ leukemic BCPs from two BCP ALL patients, as well as from two of five BCP ALL cell lines, showed a marked proliferative response to highly purified rIL-3, providing formal evidence that the observed IL-3 responses were not mediated by accessory cells. There was a high correlation between [35S]rIL-3 binding and proliferative response in colony assays, indicating that functional IL-3 receptors were detected in ligand binding assays. Scatchard plot analysis of the specific equilibrium binding data for IL-3-responsive leukemic BCPs from one BCP ALL patient and two BCP ALL cell lines yielded a straight linear regression line, indicating the existence of a single class of 60 to 210 high-affinity IL-3 binding sites/cell. The calculated apparent affinity constant (Ka) values ranged from 3.6 x 10(9) to 5.9 x 10(9) mol/L-1. Hence, the concentration of IL-3 required to produce 50% maximal receptor occupancy (Kd) was in the range of 168 to 280 pmol/L. These concentrations are approximately tenfold higher than those required to induce 50% maximal proliferative response from leukemic BCPs in colony assays, indicating that low receptor occupancy is sufficient for growth stimulation of leukemic BCPs by rIL-3. In comparison, less than 10 to 20 IL-3 molecules/cell were bound to IL-3 unresponsive leukemic BCPs even when the concentration of free-[35S]rIL-3 was as high as 2 nmol/L.(ABSTRACT TRUNCATED AT 400 WORDS)
本研究的目的是分析12例B细胞前体(BCP)急性淋巴细胞白血病(ALL)患者和5种BCP ALL细胞系中功能性白细胞介素-3(IL-3)受体的表达情况。首先研究了生物合成标记的35S重组(r)IL-3与新鲜获取的白血病骨髓原始细胞的特异性结合。在12例BCP ALL病例中的5例中,过量的冷rIL-3可显著阻断35S-rIL-3的结合,可抑制结合的百分比范围为53%至78%(平均值±标准误=65%±4%)。在这些病例中,细胞结合的放射性范围为146 cpm/10⁷细胞至1433 cpm/10⁷细胞(平均值±标准误=627±250 cpm/10⁷细胞),表明每10⁷细胞中有1至14飞摩尔(平均值±标准误=6±2 fmol)的[35S]rIL-3被特异性结合(=每细胞60至840个分子)。rIL-3以剂量依赖方式刺激白血病BCP的增殖活性,且不诱导分化,在浓度为17至34 pmol/L时观察到半数最大刺激活性。从两名BCP ALL患者以及5种BCP ALL细胞系中的两种中,通过荧光激活细胞分选仪(FACS)分离出的几乎纯的CD10⁺CD19⁺白血病BCP群体,对高度纯化的rIL-3显示出明显的增殖反应,这提供了正式证据,证明观察到的IL-3反应不是由辅助细胞介导的。在集落试验中,[35S]rIL-3结合与增殖反应之间存在高度相关性,表明在配体结合试验中检测到了功能性IL-3受体。对一名BCP ALL患者和两种BCP ALL细胞系中对IL-3有反应的白血病BCP的特异性平衡结合数据进行Scatchard图分析,得到一条直线回归,表明存在一类每细胞60至210个高亲和力IL-3结合位点。计算得到的表观亲和力常数(Ka)值范围为3.6×10⁹至5.9×10⁹ mol/L⁻¹。因此,产生50%最大受体占有率(Kd)所需的IL-3浓度在168至280 pmol/L范围内。这些浓度比在集落试验中诱导白血病BCP产生50%最大增殖反应所需的浓度高约10倍,表明低受体占有率足以使rIL-3刺激白血病BCP生长。相比之下,即使游离[35S]rIL-3的浓度高达2 nmol/L,每细胞与IL-3无反应的白血病BCP结合的IL-3分子也少于10至20个。(摘要截取自400字)